Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA1 Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib
Yotta to create end-to-end custom AI applications using platform services and NVIDIA NIM
Yotta announces six innovative AI platform services under the Shakti Cloud platform. Shakti Cloud will be the first Indian platform to offer NVIDIA NIM microservices, providing access to leading AI models like Llama, Mistral and many others to help clients in healthcare, manufacturing, telecommunica
Omega Healthcare Processes 60 Million Transactions with Enterprise AI and Automation from UiPath
Omega Healthcare Named UiPath AI25 Award Winner at UiPath FORWARD MUMBAI, India, Oct. 24, 2024 /PRNewswire/ — UiPath (NYSE: PATH), a leading enterprise automation and AI software company, announced that it is transforming operations for Omega Healthcare, a global leader in revenue cycle manag
Akastor ASA: DDW Offshore secures two contracts with an international oil company
FORNEBU, Norway, Oct. 24, 2024 /PRNewswire/ — Akastor ASA’s (OSE: AKAST) subsidiary DDW Offshore AS (“DDW Offshore”) has been awarded two one-year contracts, each with a further 24-month priced option structure, with an international oil company for the anchor handling tug s
Essity: Interim Report, Quarter 3, 2024
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — Quarter 3, 2024 – Profitable growth and higher market shares Net sales decreased 2.2% to SEK 36,274m (37,092) Organic growth amounted to 1.9%, of which volume accounted for 2.0% and price/mix -0.1%. Excluding restructuring, organic growth increase
Salt cavern energy storage brings green wealth: Greater Bay Area media visits Shandong to witness a new era of economic development
TAIAN, China, Oct. 24, 2024 /PRNewswire/ — This is a report from the Shandong office of Hong Kong Business Daily. On October 22-25, the Information Office of the People’s Government of Shandong Province hosted the 2024 Guangdong Hong Kong Macao Greater Bay Area mainstream media visit t
" title="Founder of Hua Medicine Dr. Li CHEN was awarded the “C.C. Tan Life Science Industrialization Award”
SHANGHAI, Oct. 24, 2024 /PRNewswire/ — The 17th “C.C. Tan Life Science Award” ceremony was held in Shenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C.
dsm-firmenich receives validation from the Science Based Targets initiative for its 2045 net-zero targets
KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, Oct. 24, 2024 /PRNewswire/ — dsm-firmenich, innovators in nutrition, health, and beauty, today announces that its near-term and long-term climate targets have been validated by the Science Based Targets Initiative (SBTi). By focusing on cli
" title="“K” LINE to trial Inmarsat Maritime’s new bonded network service NexusWave on “K” LINE’s fleet
LONDON, Oct. 24, 2024 /PRNewswire/ — Kawasaki Kisen Kaisha, Ltd. (“K” LINE) and Inmarsat Maritime, a Viasat company, are pleased to announce that “K” LINE will conduct a trial of Inmarsat Maritime’s new bonded network service NexusWave on “K” LINE
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI ‘JIN-A02’ in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ — J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung can
